Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than…
Browsing: pembrolizumab
Modern anti-cancer drugs work via tiny molecular motions
Modern immunotherapeutic anti-cancer drugs support a natural mechanism of the immune system to inhibit the…
SU2C research leads to FDA approval of new first-line treatment for colorectal cancer
The FDA recently approved the immunotherapy drug pembrolizumab as a first-line treatment for patients with…
The Oncology Journal Club Episode 18
Find out why coffee is so good for you and hear the team sing Baby…
ICR calls for change to bring immunotherapies to more cancer patients
Major changes to the way immunotherapy drugs are researched and evaluated are essential if they…
QBiotics announces clinical collaboration with MSD targeting unresectable melanoma
QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals,…
Use of pembrolizumab provided long-term benefits in patients with metastatic melanoma, 10-year look shows
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase…
EHA 2020: A new treatment paradigm in relapsed refractory Hodgkin lymphoma
Patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) have few treatment options when they are…
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma
Researchers at Fox Chase Cancer Center, USA, along with an international team of investigators, have…
ASCO 2020: Pembrolizumab doubles time to disease progression in patients with advanced colorectal cancer with specific DNA mutations
Front-line therapy with the immune checkpoint inhibitor pembrolizumab doubled progression-free survival vs chemotherapy in patients…